Tirzepatide
aka Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)
Mechanism
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Identification
| CAS number | 2023788-19-2 |
|---|---|
| Molecular formula | C225H348N48O68 |
| Sequence | YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSamide |
| Typical dose | 2.5–15 mg once weekly subcutaneous injection (research studies mirror clinical titration: start 2.5 mg/week, escalate by 2.5 mg every 4 weeks to max 15 mg/week) |
| Half-life | ~5 days (~120 hours) |
Vendors selling Tirzepatide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 80 mg | $297.00 | — | 99 |
| Crush Research | 20 mg | — | — | 95 |
| Crush Research | 30 mg | $199.00 | — | 95 |
| Orbitrex Peptides | 10 mg | $59.99 | — | 95 |
| Orbitrex Peptides | 15 mg | $79.99 | — | 95 |
| Orbitrex Peptides | 30 mg | $129.99 | — | 95 |
| Orbitrex Peptides | 60 mg | $199.99 | — | 95 |
| Profound Aminos | 5 mg | $69.00 | — | 95 |
| Skye Peptides | 10 mg | $89.00 | — | 90 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 6 mg | — | — | 84 |
| Peptidegurus | 10 mg | — | — | 84 |
| Peptidegurus | 12 mg | — | — | 84 |
| Peptidegurus | 15 mg | — | — | 84 |
| Peptidegurus | 16 mg | — | — | 84 |
| Peptidegurus | 30 mg | — | — | 84 |
| Peptidegurus | 50 mg | — | — | 84 |
| Reta Peptide | — | — | — | 83 |
| Cocer Peptides | 10 mg | $110.00 | — | 82 |
| Blank Peptides | 30 mg | $120.00 | — | 81 |
| Blank Peptides | 10 mg | $120.00 | — | 81 |
| Crystal Peptides | 10 mg | $99.00 | — | 66 |
| Crystal Peptides | 20 mg | $159.99 | — | 66 |
| Crystal Peptides | 30 mg | $199.99 | — | 66 |
| Peptiatlas | — | — | — | 51 |
| Peptiatlas | — | — | — | 51 |
| Zjpeptix | 30 mg | — | — | 50 |
| Hkuppeptide | 20 mg | $10.00 | — | 50 |
| MEI-PEPETIDE | — | — | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $26.00 | — | 43 |
| HongDa Peptide | — | $43.00 | — | 43 |
| zztai Peptide Ltd | — | — | — | 43 |
| MJT peptides | 5 mg | $40.00 | — | 39 |
| HK Peptide Ltd (hk peptides) | 30 mg | $150.00 | — | 37 |
| HK Peptide Ltd (hk peptides) | 60 mg | $300.00 | — | 37 |
| Apollo Peptide Sciences | 15 mg | $149.99 | — | — |
| Apollo Peptide Sciences | 20 mg | — | — | — |
| Apollo Peptide Sciences | 30 mg | $279.99 | — | — |
| Apollo Peptide Sciences | 60 mg | $489.99 | — | — |
| Apollo Peptide Sciences | 15 mg | $1399.99 | — | — |
| NG Peptide | 20 mg | $65.00 | — | — |
| Strate Labs | 10 mg | $39.95 | — | — |
| Strate Labs | 30 mg | $69.95 | — | — |
| Strate Labs | 60 mg | $149.95 | — | — |
| Bulk Peptides | 20 mg | $390.00 | — | — |
| Polaris Peptides | 60 mg | $360.00 | — | — |
| Polaris Peptides | 50 mg | $320.00 | — | — |
| Polaris Peptides | 30 mg | $250.00 | — | — |
| Polaris Peptides | 10 mg | $99.00 | — | — |
| Polaris Peptides | 5 mg | $55.00 | — | — |
Research
Objective Obesity is associated with chronic low-grade inflammation, increased cardiovascular risk, and alterations in platelet indices [1-5]. Mean platelet volume (MPV) is an easily obtainable surrogate marker that has been linked to platelet activation and inflammatory burden [4, 6-8].
source →Background Obesity is a major risk factor for chronic kidney disease (CKD), contributing to kidney dysfunction through metabolic alterations and chronic inflammation.
source →Aims To assess the effect of tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist, on cardiovascular outcomes and mortality in subjects with overweight/obesity, or type 2 diabetes mellitus (T2DM).
source →Background The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide decreased risk of cardiovascular death or worsening heart failure (HF) in patients with obesity-related heart failure with preserved ejection fraction (H…
source →Background To evaluate the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP-1 (glucagon-like peptide-1) receptor agonists.
source →Aims Tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist, was approved by the FDA for type 2 diabetes mellitus (2022) and chronic weight management (2023). Despite superior efficacy in trials, its real-world safety profile remains incompletely characterised.
source →Background Obesity is a major risk factor for the development of degenerative aortic stenosis (AS), yet no pharmacologic therapy has been proven to prevent AS onset.
source →Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used in patients with type 2 diabetes and obesity.
source →This retrospective cohort study evaluated whether semaglutide and tirzepatide reduce the risk of falls and femoral fractures in older adults with type 2 diabetes and overweight or obesity. The findings showed significantly lower risks of both outcomes compared with DPP-4 inhibitors.
source →Objective To evaluate the efficacy and safety of tirzepatide versus semaglutide in individuals eligible for pharmacotherapy for obesity disease under Japan's national insurance criteria, where obesity is defined as body mass index (BMI) ≥25 kg/m 2 with excess adiposity.
source →Introduction Metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and obstructive sleep apnoea (OSA), are characterized by a complex and interconnected pathophysiological syndrome.
source →This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity.
source →A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women
source →The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages 18-70 who are currently taking tirzepatide.
source →The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas.
source →The purpose of this research study is to evaluate what type of treatment will be beneficial for people with Crohn's disease and difficult to treat inflammation in the small bowel. Current therapies are used to control the inflammation due to Crohn's disease in your digestive tract.
source →The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period.
source →This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.
source →RCT (SURMOUNT-4): continued tirzepatide maintained weight reduction; withdrawal led to substantial regain.
source →Phase 3 RCT (SURMOUNT-2): tirzepatide for obesity in adults with type 2 diabetes; significant weight reduction vs placebo.
source →Phase 3 RCT (SURMOUNT-1): once-weekly tirzepatide produced up to ~21% mean weight loss vs placebo over 72 weeks in adults with obesity.
source →This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.
source →